Litcius/Paper detail

Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects

Loren Laine, Prateek Sharma, Darcy J. Mulford, Barbara Hunt, Eckhard Leifke, Neila Smith, Colin W. Howden

2022The American Journal of Gastroenterology82 citationsDOI

Abstract

INTRODUCTION: We assessed pharmacodynamics and pharmacokinetics of a potassium-competitive acid blocker and proton pump inhibitor in US subjects. METHODS: Healthy adults were randomized to 7-day periods of vonoprazan 20 mg once daily followed by lansoprazole 30 mg once daily or the reverse order, separated by ≥ 7 days of washout. RESULTS: Vonoprazan (N = 40) had higher proportions of 24-hour periods with intragastric pH > 4 than lansoprazole (N = 41,38) on day 1 (62.4% vs 22.6%, P < 0.0001) and day 7 (87.8% vs 42.3%, P < 0.0001). Separation in pH started ∼2.5 hours after the first dose. DISCUSSION: Vonoprazan provided more rapid and potent inhibition of intragastric acidity than lansoprazole in US subjects.

Topics & Concepts

LansoprazoleMedicineProton-pump inhibitorPharmacokineticsPharmacodynamicsPharmacologyPotassiumWashoutGastroenterologyInternal medicineChemistryOmeprazoleOrganic chemistryGastroesophageal reflux and treatmentsHelicobacter pylori-related gastroenterology studiesGastrointestinal motility and disorders